.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Accenture
Chinese Patent Office
US Department of Justice
Federal Trade Commission
Merck
McKesson
Teva
Colorcon
Moodys

Generated: September 20, 2017

DrugPatentWatch Database Preview

TACLONEX Drug Profile

« Back to Dashboard

Which patents cover Taclonex, and what generic Taclonex alternatives are available?

Taclonex is a drug marketed by Leo Pharma As and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-six patent family members in thirty-one countries.

The generic ingredient in TACLONEX is betamethasone dipropionate; calcipotriene hydrate. There are sixty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene hydrate profile page.

Summary for Tradename: TACLONEX

Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Clinical Trials: see list10
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TACLONEX at DailyMed

Pharmacology for Tradename: TACLONEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL021852-001Jan 9, 2006ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
SUSPENSION;TOPICAL022185-001May 9, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
SUSPENSION;TOPICAL022185-001May 9, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL021852-001Jan 9, 2006ABRXYesYes► Subscribe► Subscribe► Subscribe
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
SUSPENSION;TOPICAL022185-001May 9, 2008RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TACLONEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL021852-001Jan 9, 2006► Subscribe► Subscribe
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL021852-001Jan 9, 2006► Subscribe► Subscribe
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
SUSPENSION;TOPICAL022185-001May 9, 2008► Subscribe► Subscribe
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL021852-001Jan 9, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TACLONEX

Drugname Dosage Strength RLD Submissiondate
calcipotriene and betamethasone dipropionateOintment0.005%/0.064%Taclonex3/31/2010

International Patent Family for Tradename: TACLONEX

Country Document Number Estimated Expiration
Japan2004512297► Subscribe
World Intellectual Property Organization (WIPO)0234235► Subscribe
MexicoPA03003511► Subscribe
Denmark1178808► Subscribe
Cyprus1114420► Subscribe
China1173703► Subscribe
Norway329486► Subscribe
Australia9163701► Subscribe
Hungary230005► Subscribe
China1633280► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Harvard Business School
Express Scripts
Citi
QuintilesIMS
Teva
Queensland Health
US Army
Mallinckrodt
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot